Access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio expands our genetic engineering toolkit and strengthens our ability to speed up and optimize strain development across Dyadic’s ...

India's GlaxoSmithKline Pharmaceuticals reported slightly higher second-quarter profit on Thursday, led by steady demand for ...

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of ...

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, ...

GSK plc ( GSK) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Ladies and gentlemen, a very warm welcome to the GSK Q3 2025 Results Call. I'm delighted to be joined today by Emma Walmsley, Luke ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer drugs in the third quarter.

"Sales grew in all areas, with particularly strong performances in Specialty Medicines, driven by double-digit growth in Respiratory Inflammation & Immunology, Oncology and HIV," said Emma Walmsley, ...

British pharmaceutical group GSK on Wednesday raised its full-year outlook after strong sales growth in its third quarter, ...

Under the deal, France-based Syndivia will receive an upfront payment, as well as development and commercial milestone payments, totaling up to £268 million. ・GSK, meanwhile, will undertake ...

GSK's London-listed shares fell about 2% on Friday after the U.S. Food and Drug Administration approved only one of two treatment combinations with the British firm's blood cancer drug, limiting the ...